Private Market View

Kailera Therapeutics (NAS: KLRA)

Waltham, MA · Founded 2024 · Publicly Held

Last price · $/share
Implied valuation
$1.5B
Total raised
$1.6B
Last round

Key facts

  • Kailera Therapeutics (NAS: KLRA)’s last known valuation is $1.5B (Oct 2025).
  • It has raised $1.6B; the latest was IPO ($625.0M) in Apr 2026.
  • Notable investors include Qatar Investment Authority, Bain Capital, The Invus Group, RTW Investments, Atlas Venture14 tracked in total.
  • 2 institutional filers report fund marks on Kailera Therapeutics (NAS: KLRA) across 5 filings.
  • Status: Publicly Held.
Free account
See the evidence behind this price
  • ·The complete investor list — 14 names
  • ·Watchlist + deal alerts for Kailera Therapeutics (NAS: KLRA)
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Kailera Therapeutics (NAS: KLRA) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Kailera Therapeutics (NAS: KLRA)

Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

Sector
Healthcare
HQ
Waltham, MA, United States
Founded
2024
Employees
140
Ownership
Publicly Held
PA Mark — not yet priced

Kailera Therapeutics (NAS: KLRA) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Kailera Therapeutics (NAS: KLRA) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

2 filers · latest May 2026

2 SEC-registered funds reported 5 fair-value marks on Kailera Therapeutics (NAS: KLRA) between Apr 2026 and May 2026. Filer-level marks and implied $/share are available to Pro members.